a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
Published 1 year ago • 152 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
1:52
parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer
-
2:47
talave: induction talazoparib with parp inhibition in breast cancer
-
5:12
regional analysis of talazoparib for treatment of advanced breast cancer w germline brca1/2 mutation
-
3:52
talazoparib in locally advanced or metastatic breast cancer
-
9:21
dr. litton on activity of talazoparib in advanced brca1/2 breast cancer
-
4:12
impact of race on clinical, socioeconomic, genomic characteristics among patients with mbc
-
3:52
the phase 3 embraca study of talazoparib in brca-related metastatic breast cancer
-
2:07
parp inhibitors and the embraca study of talazoparib in brca-related metastatic breast cancer
-
6:01
neoadjuvant talazoparib for brca 1/2 mutated triple negative breast cancer
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
2:01:14
act genomics dinner symposium | moving from brca1/2 to hrd: beyond woman’s cancers
-
1:50
progress for gilteritinib and quizartinib for aml in the first-line setting
-
1:57
dr. sessa discusses atr inhibitors in brca-mutated tumors
-
4:51
telazoparib vs physicians choice for patients with mbrca1 breast cancer
-
1:42
nodal recurrence following axillary downstaging with neoadjuvant chemotherpay omission of alnd
-
0:58
use of parp1-selective and atr inhibitors to target ddr signalling pathway
-
1:39
phase ib trial of bintrafusp alfa for advanced urothelial cancer
-
1:05
dr. garcia on a trial analyzing the parp inhibitor veliparib
-
2:43
study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer